SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...

Age-related macular degeneration (AMD) is an eye condition that can affect central vision, which is the vision used for activities such as reading and recognizing faces. In people with wet AMD, ...

Wet age-related macular degeneration (AMD), or advanced neovascular AMD, affects central vision and can lead to rapid, irreversible vision loss. It often requires treatment to preserve eyesight.

Important updates on wet age-related macular degeneration from the 2026 American Society of Retina Specialists Annual Meeting are reviewed by Dr Sunir Garg of Wills Eye Hospital in Philadelphia. Dr ...

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

The market for treatments of macular degeneration, cited as the leading cause of blindness in the elderly, is growing rapidly. Macular degeneration is a condition where abnormal blood vessels grow ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...